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INTRODUCTION
Brain metastases (BMs) represent a significant healthcare 
problem. Tsao et al., estimated that 20–40% of  patients 
with cancer will develop BMs during the course of  their 
illness.[1] More than 80% of  BMs are detected after 
the primary tumor has been diagnosed (metachronous 
metastases) and less frequently, they are the first 
manifestation of  disease or are diagnosed at the same 
time as the primary tumor (synchronous metastases).
Schouten affirmed that literature data reported that, the 
5 years cumulative incidence of  BMs was approximately 
16%, 10%, 7%, 5%, and 1% for lung cancer, renal 
cell cancer, melanoma, breast cancer, and colorectal 
carcinoma, respectively.[2]
Due to the advanced nature of  disease at the time of  
presentation in patients with intracranial metastases, particularly 
if  symptomatic, treatment options have been limited.
According to Borgelt et al., all patients with BMs typically 
receive corticosteroids, which will improve edema and 
neurologic symptoms in approximately 70% of  patients, 
nonetheless, the median survival with steroids alone is 
approximately 2 months.[3]
The irradiation of  the whole brain radiotherapy (WBRT) 
remains the most commonly undertaken treatment 
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Aim: Brain metastases (BMs) are a common event in the progression of many human cancers. The aim of this 
study was to evaluate the potential prognostic factors for the clinical identification of a subgroup of patients that 
could benefit from whole brain conformal radiotherapy (WBRT). 
Materials and Methods: From January 2010 to February 2014, 80 patients with a diagnosis of BMs underwent 
WBRT at our Radiation Oncology Department, San Luigi Hospital, Italy. Among them, 36 medical records 
were retrospective reviewed. Gender, age, Karnofsky performance status (KPS), number of BMs on computed 
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absence of necrosis pattern, and histology of primary tumor were analyzed. Univariate and multivariate analyses 
were performed. 
Results: In our cohort of patients, significant prognostic factors for 20 months overall survival was KPS > 70, 
while a statistical trend (P = 0.098) was registered regarding primary breast. 
Conclusion: WBRT can be still considered a standard and effective treatment in patients with BMs. High KPS 
and breast cancer primary tumor seem to be useful parameters for characterize a subgroup of patients with 
more favorable prognosis.
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for multiple metastases and is associated with increases 
in the median survival, compared with steroids alone, to 
approximately 4–6 months. Because of  WBRT leads to 
serious neurologic or neuro‑cognitive deficits (motion and 
eloquio reduction), in selected subgroup of  patients this 
technique must be discussed in relation to other therapeutic 
alternatives such as stereotactic radiotherapy (SRT) and 
radiosurgery (SRS) or the use of  new chemotherapy drugs.[4]
However, for patients with short life expectancy and poor 
performance status, supportive care alone may be the more 
appropriate oncologic approach.
In according to data published on 2012 from “international 
practice survey on the management of  BMs” different 
treatment schedules are administered in WBRT, particularly 
30 Gy in 10 daily fraction is most used in USA and Europe 
while 20 Gy in five daily fractions is preferred Canada and 
Australia/New Zeeland.[3,5,6]
Survival prediction model that might lead decision making 
when choosing between best supportive care and WBRT 
were developed.[7]
The aim of  our retrospective study was to analyze the 
outcomes of  patients with newly diagnosis of  multiple BMs 
referred to our Institution for WBRT, in order to identify 
the prognostic factors useful for clinical identification of  a 
subgroup that really benefits from radiation therapy.
MATERIALS AND METHODS
From January 2010 to February 2014, 80 patients with 
diagnosis of  BMs, not eligible for SRT or SRS, underwent 
WBRT at our Institution. In this preliminary study, were 
retrospective anlyzed 36 medical records of  patients, with a 
mean age of  63 years (range from 30 to 79), selected because 
they had performed a radiation treatment comparable in 
terms of  contouring, dose, and fractionation.
With the intent of  detecting several prognostic factors 
useful to identify patients who really benefit from 
WBRT compared to those to be addressed to supportive 
care alone, were examined all the following clinical 
and radiological parameters: Gender, age (≤50 vs. 
51–60 vs. 61–70 vs. >70 years), Karnofsky performance 
status (KPS) (KPS < 70 vs. KPS ≥ 70), number of  
BMs on computed tomography (CT) and/or magnetic 
resonance images (≤5 and >5), presence or absence of  
perilesional edema, presence or absence of  necrosis 
pattern, and histology of  primary tumor [Table 1]. In our 
retrospective study, these data were extrapolated from 
computerized medical records, which were recorded 
by the radiation oncologist at the time of  the medical 
examination.
As a retrospective study, the Ethics Committee approval 
was not required.
Although crucial in the choice of  treatment strategy, 
predicting accurately the length of  survival of  BMs cancer 
patients is difficult because systemic therapies often 
led patients’ survival beyond estimated survival rates. 
Therefore, in this first analysis status of  systemic disease 
was not considered. Steroid therapy was administrated in 
all patients along WBRT course, with a tailoring dosage in 
relation to the neurological symptoms and signs reported 
before, during, and after treatment.
Patients will be immobilized in the supine position using an 
individually customized thermoplastic face mask (Klarity 
Medical and Equipment Co. Ltd., Guangzhou, China). 
Table 1: Characteristic of patients
Number of patients (%)
Age (years)
<50 3 (8)
51-60 11 (21)
61-70 9 (35)
>70 13 (36)
Gender
Female 13 (36)
Male 23 (64)
KPS
KPS ≥70 7 (19)
KPS <70 29 (81)
Number of brain metastases
≤5 13 (36)
>5 23 (64)
Presence of perilesional edema
No 8 (22)
Yes 28 (78)
Presence of necrosis pattern
No 32 (89)
Yes 4 (11)
Histology of primary cancer
SCLC 4 (11)
NSCLC 17 (47)
Breast cancer 8 (22)
Other tumors 7 (20)
Radiation schedule
30 Gy/10 Fx (3 Gy/day) 25 (70)
30 Gy/12 Fx (2.5 Gy/day) 11 (30)
KPS: Karnofsky performance status; NSCLC: Nonsmall cell lung cancer, SCLC: Small 
cell lung cancer; Fx: Fractions
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For treatment planning a noncontrast‑enhanced CT for 
virtual simulation (AcqSim, Philips, the Netherlands) was 
performed, including whole brain down to the inferior 
plate of  the II cervical vertebral body. Images were 
transferred to a treatment planning system (Oncentra 
MasterPlan v3.3, SP 3, Nucletron, Elekta, Atlanta, GA, 
USA). Planning target volume (PTV) was generated 
adding 5 mm margin to the whole brain clinical target 
volume. The selected organ at risks such as a lens, optic 
nerves, eyeballs, and spinal cord were outlined. WBRT 
was administered using two opposite shaped latero‑lateral 
fields with 45° collimator rotation. The field‑in‑filed 
technique was implemented in order to reduce the 
percentage of  PTV receiving more than 110% (V 110%) 
and 107% (V 107%) prescribed dose, as well as Dmax. 
A dose of  2.5–3 Gy was delivered with six megavoltage 
machine, 5 days/week, for 12–10 fractions for a total 
dose of  30 Gy.
All patients alive at the time of  analysis were censored with 
the date of  last follow‑up. Survival was calculated from the 
1st day after the end of  WBRT.
Statistical univariate analysis (Kaplan‑Meier method and 
log‑rank test) and multivariate analysis (Cox hazards 
proportional model) were performed in order to identify 
prognostic factors influencing survival in case of  WBRT 
administration. A P = 0.05 was considered statistically 
significant.
RESULTS
Males and females constituted the 64% and 36% of  the 
group, respectively. Nonsmall cell lung cancer (NSCLC) 
represented the most common histological type (47.5%) 
followed by breast cancer (22%) [Table 1]. All patients 
completed the WBRT planned course.
The overall median survival time was 6 months [Figure 1]. 
The 6, 12, and 20 months overall survival (OS) rate were 
47%, 19%, and 17%, respectively.
In our clinical records, patients with breast cancer had 
a better median survival of  9 months compared with 
3.5 months for NSCLC.
On univariate analysis, high KPS score, absence of  
perilesional edema and the number of  BMs were <5 
were significant prognostic factors correlated with 
OS (P = 0.0003, P = 0.03 and P = 0.037, respectively) 
[Figures 2‑4 and Table 2].
Figure 2: Karnofsky performance status and overall survival
Figure 3: Presence/absence of edema around metastatic lesions and 
overall survival correlation
Figure 1: Median overall survival time 
On multivariate analysis, performed with cox regression, 
of  all potential prognostic factors for OS only KPS 
has been confirmed statistically significant (P = 0.006), 
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while a trend was showed for breast cancer primary 
tumor (P = 0.098) [Table 3 and Figure 5].
During the treatment course, 44.4% of  patients had 
a tolerable toxicity profile whereas 28% experienced 
symptomatic intracranial hypertension syndrome and 
neurological deficits that required inpatients supportive 
setting. After WBRT, the most frequents adverse events were 
headache and dizziness (25% of  incidence in both cases) 
whereas 25% of  treated patients showed no symptomatic 
effects. Only two patients discontinued definitively steroid 
therapy after WBRT. Finally, nevertheless the radiation dose 
to the scalp ranged between 28 and 31 Gy in all patients, in 
four cases we registered. Hair regrowth after 3 months, from 
the end of  WBRT probably, due to individual biological 
parameters. No treatment‑related deaths were identified.
DISCUSSION
Patients with BMs are a heterogeneous population and 
treatment depends on the individual clinical setting. There 
is a lack of  high‑quality randomized evidence to clarify the 
value of  WBRT versus supportive care alone in patients 
with BMs, while no guidelines are available for clinicians 
to identify which subsets of  patients should be managed 
with supportive care alone, without WBRT.
The aim of  this retrospective study was to assess the 
effectiveness of  WBRT in adult patients with newly 
diagnosed BMs and to individuate potential prognostic 
factors useful to drive therapeutic choice that is, WBRT 
versus supportive care. In the present study, all patients 
were treated as homogeneously as possible. The limitations 
of  our preliminary study are related to inadequate 
consideration about the information on the status of  
systemic disease at the moment of  WBRT and the extensive 
range of  time in which patients were retrospectively 
enrolled.
Historically, WBRT has been utilized as the main 
treatment modality for the management of  BMs.[8] The 
addition of  WBRT to steroids extended median survival 
to 3–6 months,[9‑11] but in the last decade there has 
been mounting evidence regarding the toxic effects of  
WBRT, especially serious neurocognitive impairments.[11] 
Therefore, the clinical indication of  WBRT must be the 
result of  the appropriate balance between the potential 
benefits and possible sequelae, taking into account the 
clinical implementation of  modern radiation therapy 
approaches, such as SRS or hippocampal‑avoidance WBRT, 
Table 2: Univariate analysis of survival
P
Age 0.2
Gender 0.3
KPS 0.0003
Number of brain metastases 0.037
Presence of perilesional edema 0.003
Presence of necrosis pattern 0.3
Histology of primary cancer 0.308
The P‑values were obtained from the log‑rank test. KPS: Karnofsky performance status
Table 3: Multivariate analysis of survival
Hazard ratio 95% CI P
KPS 0.09 0.02-0.52 0.006
Number of brain metastases 0.51 0.19-1.38 0.184
Presence of perilesional edema 1.69 0.47-6.09 0.421
Primary breast cancer 0.32 0.08-1.240 0.098
Primary NSCLC 1.17 0.42-3.23 0.761
KPS: Karnofsky performance status; CI: Confidence interval; NSCLC: Nonsmall cell 
lung cancer
Figure 5: OS in relation to histology of primary tumorFigure 4: The number of brain metastases on radiological images and 
overall survival relation
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and patients performance status, toward a more tailored 
and disease‑specific treatment management.[6]
Numerous factors in addition to the presence of  active 
systemic disease have been correlated with poor patient 
survival: KPS < 70 poor neurologic status, number of  BMs, 
age, time from primary to BMs, and tumor histology.[12,13]
In patients affected with BMs, literature data show that 
histology of  primary tumor must be considered in order 
to optimize the therapeutic choice, because there are 
histological subtypes associated with more favorable OS, 
such as breast cancer versus others more radio‑resistant 
correlated with poor patient survival, such as lung cancer 
or melanoma.[14]
In particular, to date, diagnosis of  central nervous system 
involvement in breast cancer patients is becoming more 
common because of  treatment strategies are improving 
with a longer OS.[15]
In order to individualized a subgroup of  patients that 
benefit from WBRT, Gaspar et al., analyzed 1200 patients 
from three consecutive radiation therapy oncology 
group (RTOG) trials, which tested several different WBRT 
fractionation schemes and radiation sensitizers, using the 
RTOG recursive partitioning analysis (RPA) prognostic 
system. A prognostic subgroup of  patients was identified 
according to age at diagnosis, absence or presence of  
extracranial disease, KPS score and status of  primary 
cancer. On the basis of  this analysis, the median survival of  
patients with BMs ranges from 2.3 to 7.1 months, opening 
the debate regarding whether the patients in the best 
prognosis category should or should not be treated with 
more aggressive therapies to control intracranial disease.[16] 
However, the RPA classification failed to correctly predict 
long‑term survival in the majority of  patients.[17]
Gállego et al., in a recent publication confirmed the 
importance of  performance status assessment in the 
therapeutic decision. In patients with widely disseminated 
cancer and short life expectancy, WBRT did not significantly 
improve survival compared with supportive palliative 
care alone. By contrast, in patients with the extra cranial 
controlled systemic disease, good performance status, 
and a limited number of  BMs WBRT may be a beneficial 
therapeutic option both for the quality of  life and survival.[18]
Multivariate analysis of  our preliminary data shows that 
the KPS correlates with significant evidence to a better 
prognosis while a statistically significant trend is highlighted 
for breast cancer, and this is in agreement with literature 
data. Regarding the number of  BMs was not detected 
statistical significance, as it could be seen from the literature, 
perhaps for the small power of  our sample.
Knowledge of  prognostic factors of  patients with 
BMs is crucial for appropriate therapeutic choice and 
our preliminary study indicate that, even if  in this 
heterogeneous group of  few patients, KPS and breast 
cancer primary tumor are parameters useful to help 
clinicians to individualize well‑selected patients with good 
life expectancy, in according with literature. Especially 
KPS, beyond the small number of  patients of  our 
preliminary study was anyway an important prognostic 
factor, immediate and easily available, useful in daily clinical 
practice everywhere.
CONCLUSIONS
Whole brain conformal radiotherapy continues to be an 
efficacious treatment in the management of  BMs. There 
is clear recognition that not all BMs patients that undergo 
WBRT have survival outcome equivalently. Patients with 
poor performance status, extensive brain disease, and 
unfavorable primary tumor histology have less evident 
beneficial effects from WBRT and probably are best 
managed with supportive care alone.[7]
Taking into account specific prognostic factors, in our 
preliminary, high KPS, and breast cancer primary tumor 
seem to characterize a subgroup of  patients with favorable 
prognosis.
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